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Summary 
Erythropoietin (EPO) is the primary humoral regulator of erythropoiesis and no other factor 
has previously been reported to support proliferation and terminal maturation oferythroid cells 
from hemopoietic stem cells. Here we show that stimulation ofglycoprotein (gp130) by a com- 
bination of  recombinant human soluble intedeukin 6 receptor (slL-6R) and IL-6 but not slL-6R 
or IL-6 alone can support proliferation, differentiation, and terminal maturation of erythroid 
cells in the absence of EPO from purified human CD34 + cells in suspension culture containing 
stem cell factor (SCF). A number of erythroid bursts and mixed erythroid colonies also devel- 
oped in methylcellulose culture under the same combination. The addition ofanti-gpl30 mono- 
clonal antibodies but not anti-EPO  antibody to the same  culture completely abrogated the 
generation of erythroid cells. These results clearly demonstrate that mature erythroid cells can 
be emerged from hemopoietic progenitors without EPO in vitro. Together with the previous 
reports that human sera contain detectable levels of slL-6R, IL-6, and SCF, current data sug- 
gest that gp130 signaling in association with c-kit activation may play a role in human erythro- 
poiesis in vivo. 
G 
lycoprotein (gp130) 1 is the signal transducing receptor 
component commonly employed by receptor com- 
plexes for the cytokines of the IL-6 family, i.e., IL-6, leu- 
kemia inhibitory factor (LIF), oncostatin M  (OSM), ciliary 
neurotrophic factor (CNTF), and IL-11 (1-5). Homodimer- 
ization ofgpl30 induced by IL-6 upon binding IL-6R and 
heterodimerization  of LIFR-gp130  induced  by  CNTF, 
LIF, or OSM  are believed to trigger signaling leading to 
cellular response through the activation of, for instance, Ja- 
nus kinases-STAT3 (for acute phase response factor or sig- 
nal transducer and activator of transcription;  3)  and Ras/ 
mitogen-activated protein kinase pathways  (6,  7).  Recent 
studies (1-8) have shown that gp130 is expressed in a wide 
variety of cells,  whereas  expression of the ligand-binding 
receptor  chains  for  the  IL-6  family  of cytokines  shows 
somewhat  restricted distribution  and  does not  necessarily 
~Abbreviations used in this paper: BM, bone marrow; EPO, erythropoietin; 
FBS, fetal bovine serum; gp,  glycoprotein; MNC, mononuclear cells; 
SCF, stem cell factor;  slL-6R, soluble IL-6R. 
parallel that ofgpl30. The ubiquitously expressed gp130 in 
a broad range of tissues suggests  that it may play a vital role 
in vivo. To date, the physiological role of gp130  remains 
largely unknown, since gp130 has been studied primarily in 
cultured cell lines. 
A  soluble form of IL-6 receptor (slL-6R),  lacking the 
transmembrane and the intracytoplasmic domains, has been 
shown to be present in human serum and to bind IL-6 with 
a binding affinity similar to that of the entire IL-6R mole- 
cule.  gp130  associates  with  both  membrane-anchored 
IL-6R and slL-6R when the receptor is occupied by IL-6 
and transduces signals  (2, 6). We have recently shown that 
gp130 signaling,  initiated by a complex of slL-6R/IL-6, in 
the presence of stem cell factor (SCF)  potently stimulates 
the ex vivo expansion of human primitive progenitor cells 
(9).  To address  the physiological role of gp130 on human 
hemopoiesis in more detail, we have examined the effects 
of gp130  stimulation on the proliferation and differentia- 
tion of purified human CD34  + cells by focusing on eryth- 
ropoiesis. 
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Cell Preparation.  Human umbilical cord blood, collected accord- 
ing to institutional guidelines, was obtained during normal full- 
term deliveries. Human bone marrow  (BM)  was obtained from 
healthy  volunteers  with  informed  consent.  Mononuclear  cells 
(MNC) were separated by Ficoll/Paque density gradient centrifu- 
gation after depletion of  phagocytes with silica (Immuno Biologi- 
cal Laboratories, Fujioka, Japan) (10).  CD34 + cells were purified 
from MNC by using Dynabeads M-450 CD34 and DETACHa- 
BEAD CD34  (Dynal, Oslo, Norway). 85-95% of the cells sepa- 
rated were CD34 + by fluorescence-activated cell sorting (Ortho 
Diagnostic Systems, Inc., Westwood, MA) analysis. 
Receptor and Cytokines.  Recombinant human IL-6 and slL-6R 
were prepared as described (11).  Recombinant human SCF was 
supplied by Amgen  Inc.  (Thousand  Oaks,  CA).  Recombinant 
human IL-3 and erythropoietin (EPO) were generously provided 
by Kirin Brewery Co.  (Tokyo, Japan).  All the  cytokines were 
pure recombinant molecules and were used at concentrations that 
induced optimal response in  methylcellulose culture  of human 
hemopoietic cells.  These concentrations are 100  ng/ml of SCF, 
200 U/ml oflL-3, and 2 U/ml of EPO. 
Preparation of Abs.  Preparation  of anti-human  gp130  mAbs 
(GPX7, GPX22, and GPZ35) has been described (12, 13). The three 
mAbs recognize different epitopes on gp130 and were shown to 
inhibit IL-6-mediated biological response through inhibition of 
the IL-6-induced association ofgpl30 and IL-6 receptors. Anti- 
human IL-6R (PM1) mAb was prepared as described (14).  PM1 
was shown to inhibit IL-6-mediated biological response through 
inhibition of the binding of IL-6R to IL-6. Rabbit anti-human 
EPO Ab (IgG K-5) was provided by Kirin Brewery Co. (15). 
Suspension Culture.  2,000 CD34 § cells were cultured in 1 ml 
of  culture mixture containing c(-medium (Flow Laboratories, Rock- 
ville, MD), 20% fetal bovine serum (FBS; HyClone Laboratories 
Inc., Logan, UT),  1% crystallized and deionized fraction V BSA 
(Sigma Chemical Co.,  St.  Louis, MO),  and different combina- 
tions of cytokines in 24-well tissue plates (Nunc, Roskilde, Den- 
mark) at 37~  in a humidified atmosphere flushed with 5% CO2/ 
5% 02/90% N 2. For serum-free suspension culture, FBS and BSA 
were replaced by 2% pure BSA, 10 ~g/ml of insulin, 200/ig/ml 
of transferrin (all from  Sigma Chemical Co.),  0.01  mM  2-ME 
(Eastman Organic Chemicals, Rochester, NY), and 40 ~g/ml of 
low density lipoprotein (Sigma Chemical Co.) using a modifica- 
tion of a previously reported method (16).  Cultures were demi- 
depopulated weekly by the removal of half the culture volume, 
which was then replaced by newly prepared culture mixture with 
additional feeding of the same combinations ofcytokines. Cells in 
the collected medium were washed, counted in a hemocytome- 
ter, cytocentrifuged, and stained. Anti-gp130 mAbs, anti-IL-6R 
mAb, or anti-EPO Ab were added at the beginning of the culture 
for blocking studies. 
Clonal Culture.  The  purified  CD34 +  cells  and  BM  MNC 
were incubated in triplicate at concentrations of 500 cells/ml for 
CD34 + cells and 2.5  ￿  104 cells/m] for BM MNC in methylcel- 
lulose culture as previously reported (17, 18). 1 ml of culture mix- 
ture containing cells, a-medium, 0.9% methylcellulose (Shinetsu 
Chemical, Tokyo, Japan), 30%  FBS, 1% BSA, 0.05  mM 2-ME, 
and various combinations ofcytokines with or without slL-6R was 
plated in each 35-mm standard nontissue culture dish (Nunc, Na- 
perville, IL) and incubated at 37~  in a humidified atmosphere 
flushed with 5% CO2 in air. Serum-free methylcellulose culture 
contained  components  identical  to  those  in  serum-containing 
culture except 1% pure BSA, 300  p.g/ml of human  transferrin, 
160  Ixg/rnl of soybean lecithin (Sigma Chemical  Co.),  and  96 
838 
v,g/ml  of cholesterol  (Nacalai Tesque,  Kyoto, Japan)  replaced 
BSA and FBS (19). All cultures were scored at day 7 for CFU-E- 
derived colony and day 14  for BFU-E  and  CFU-Mix-derived 
colonies  according  to  the  criteria  as  reported  previously  (10, 
17, 18). 
Cytochemical and Immunological  Staining.  Cytocentrifuge prepara- 
tions from suspension culture and methylcellulose culture were 
stained for the observation of cellular morphology. Staining with 
May-Grtinwald-Giemsa and benzidine were performed by con- 
ventional  methods.  Immunostaining  with  the  alkaline  phos- 
phatase antialkaline phosphatase method using mAbs ofantiglyco- 
phorin A and antihemoglobin o~ chain (Cosmo Bio., Tokyo, Japan) 
were carried out as described previously (20). Briefly, cytocentri- 
fuged samples were fixed with buffered formalin-acetone at 4~ 
washed with Tris-buffered saline (Wako, Osaka, Japan), and pre- 
incubated with normal rabbit serum to saturate the Fc receptors 
on the cell surface.  After washing, the samples were successively 
incubated with mouse mAbs and rabbit anti-mouse IgG Ab (Medi- 
cal and Biological Laboratories, Nagoya, Japan); they were then 
reacted with  calf intestinal alkaline phosphatase-mouse  mono- 
clonal antialkaline phosphatase  complex  (Dako,  Osaka, Japan). 
Alkaline phosphatase activity was detected with naphthol AS-TR 
phosphate sodium salt (ClsH13C1NOsPNa2;  Sigma Chemical Co.) 
and Fast red TP,. salt (both from Sigma Chemical Co.) in pH 7.6, 
40 mmol/liter barbital buffer (Wako) containing levamisole (Sigma 
Chemical Co.) to inhibit nonspecific alkaline phophatase activity. 
Positive cells were stained with reddish granules. 
Statistical Analysis.  For statistical comparison  in  scoring the 
number oferythroid cells and colonies, Student's t test was applied. 
The significant level was set at 0.05. 
Results 
Dose-dependent  Effect of slL-6R and IL-6 on Erythroid  Cell 
Generation from CD34 + Cells.  When  CD34 +  cells isolated 
from human cord blood MNC  were cultured with slL-61q. 
in the presence oflL-6 and SCF for 14 d, total cell number 
dramatically increased in accordance with the concentration 
ofslL-6R (Fig.1 A). This increase in a dose-dependent man- 
ner began at 80  ng/ml  of slL-6R and  reached a plateau at 
1,280 ng/ml. It is interesting to note that a number oferyth- 
roid cells were observed on the cytospin preparations from 
the cultures containing slL-6P,. The nature of erythroid cells 
was confirmed by benzidine staining and immunostainings 
with  mAbs  of antiglycophorin A  and  antihemoglobin  o~. 
Erythroid cells, including erythroblasts and erythrocytes, de- 
tectable at 80 ng/ml of slL-6R, increased dramatically in a 
similar fashion to the total cell increase. Morphological anal- 
ysis showed that ~70% of total cells were erythroid cells at 
a  concentration  of slL-6R  >1,280  ng/ml.  In the  absence 
of IL-6,  however,  slL-6P, failed to  increase the  total cell 
number and no erythroid cells were found (Fig.  1 B). The 
increase  in  the  total  cell  and  erythroid  cell  numbers  was 
also dependent on the concentration of IL-6, and maximal 
increase was  obtained at concentrations  exceeding 50  ng/ 
ml when  1,280 ng/ml ofslL-6R was present (Fig. 1 C). In 
contrast, in the absence of slL-6P,, increase in the total cell 
number  by  IL-6 was  much  lower  and  no  erythroid  cells 
were  detected even  at  concentrations  >50  ng/ml  (Fig.  1 
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Figure 1.  Proliferative  activity  ofslL-6R and IL-6 on the generation of 
total cells (open  circles)  and erythroid cells (filled  circles)  from human CD34  + 
cells in  the  presence of SCF in serum-containing suspension culture. 
2,000 cord blood CD34  + cells were initiated in all cultures and results 
were examined at day 14. Growth of CD34  + cells under various concen- 
trations ofslL-6R in the presence (A) or absence (B) of 50 ng/ml oflL-6. 
Growth ofCD34 + cells  under various concentrations oflL-6 with SCF in 
the presence (C) or absence (D) of 1,280 ng/ml ofslL-61k. 
D). The same results were also obtained when CD34 + cells 
purified from human BM MNC were used.  These results 
clearly indicate that slL-61k is functional and capable ofsfm- 
ulating the expansion of erythroid as well as total cells from 
CD34 + cells in serum-containing culture in the presence of 
IL-6 with SCF.  They also  show that slL-61k at 1,280 ng/ 
ml and IL-6 at 50 ng/ml appear to be the optimal concen- 
trations for the generation of erythroid cells. 
Erythroid  Cell  Production from  CD34 +  Cells  by  slL-6R, 
IL-6, and SCF in Serum-free Suspension Culture.  To  exam- 
ine  the  slL-6R/IL-6  complex-induced  erythropoiesis  in 
more detail,  and  to  exclude  the  possible influences  of an 
unknown factors(s)  existing in FBS on the results obtained 
in serum-containing culture, serum-free suspension culture 
of the  CD34 + cells over a period of 3 wk was carried out 
using the  optimal concentrations of sIL-6R and IL-6 deter- 
mined  above.  The  characteristics  of expanded  erythroid 
ceils  were  examined  weekly.  A  more  significant  synergy 
between  sIL-6R  and  IL-6  in  the  increase  of total  and 
erythroid cells in the presence of SCF was observed in the 
serum-free cultures.  A  combination of sIL-6R, IL-6, and 
SCF in serum-free culture promoted 38-, 530- and 2,170- 
fold expansion of total cell number at days 7, 14,  and 21  of 
culture, respectively, whereas SCF alone or in combination 
with IL-6 showed only a 2.2- or 7.5-fold expansion even at 
day 21  of culture. Differential cell counts of expanded cells 
on the cytocentrifuge preparations indicated the presence of 
mainly blast cells at day 7 of culture (Fig. 2 a for representa- 
tive staining). A high proportion of erythroid cells was ob- 
served in serum-free suspension cultures with the combina- 
tion  of sIL-6R,  IL-6,  and  SCF  at  days  14  and  21.  The 
erythroid cells  were positively immunostained with mAbs 
of antiglycophorin A  (Fig.  2 b) and antihemoglobin ot (Fig. 
2  c).  Some of the  erythroid cells  differentiated to normo- 
839  Sui et al. 
blast and enucleated erythrocyte stages (Fig.  2 d). At day 21 
of culture, most of the erythroid cells differentiated to nor- 
moblast stage, and many enucleated erythrocytes were ob- 
served. Weekly analyses  of the  absolute number of eryth- 
roid cells generated in serum-free suspension cultures with 
various combinations of cytokines and slL-61K are summa- 
rized in  Table  1.  The  combination of slL-6R,  IL-6, and 
SCF  enhanced  the  number of cells  in  the  suspenion  cul- 
ture, in which erythroid cells were predominant. No other 
combination  except  that  of SCF  and EPO  could  induce 
such a dramatic increase. Approximately 79 and 69% of the 
cells generated by this combination were erythroid cells on 
days 14 and 21  of culture,  respectively. The total number 
of erythroid cells produced by the combination of slL-61k, 
IL-6, and SCF was significantly higher  than that of other 
groups  (p  <0.01-0.0001),  and was about 4-  and 3.5-fold 
larger than that produced by EPO alone or by a combina- 
tion  of slL-61K,  IL-6,  and EPO,  respectively on  day  14. 
The respective increase observed on day 21 was about 150- 
and  50-fold.  Predominant  effects  of the  combination  of 
slL-61K, IL-6, and SCF on the generation of erythroid cells 
were also observed with BM CD34 + cells. As is well docu- 
mented, a combination of EPO and SCF also significantly 
stimulates the generation of erythroid cells, but appears in a 
growth  pattern  different  from that  of slL-61k,  IL-6,  and 
SCF.  More than 90%  of the  generated cells  by EPO  and 
SCF  are erythroid cells  at day 7,  whereas significant pro- 
duction oferythroid cells induced by a combination ofslL- 
61k, IL-6, and SCF was observed at day 14. At day 21, the 
total number of erythroid cells produced in the two groups 
was  comparable,  and  although  statistical  differences were 
not reached, a combination of slL-61k, IL-6, and SCF ap- 
peared to induce a higher number of erythroblasts, whereas 
EPO with SCF generated more enucleated erythrocytes. 
These  results  indicate  that  the  dramatic  generation  of 
erythroid cells by slL-61K/IL-6 needs the combination with 
SCF.  To  examine  the  possible  synergy  of slL-6R/IL-6 
with other cytokines, suspension culture ofCD34 + cells sup- 
plemented with different combinations ofslL-61k and IL-6 
with  various  cytokines  was  carried  out.  slL-61K/IL-6  in 
combination with IL-3 also  generated erythroid cells,  but 
to a lesser extent compared with the combination with SCF 
(Table 1). No erythroid cells were detected in the cultures 
containing slL-61K/IL-6 together with either G-CSF, GM- 
CSF,  IL-1[3, TGF-[3, insulinlike  growth factor 1  (IGF-1), 
macrophage inflammatory protein, platelet derived growth 
factor,  fibroblast growth  factor  (FGF),  or TNF  (data  not 
shown). 
Erythroid  Colony  Formation  by  slL-6R,  IL-6,  and  SCF. 
It is likely that the development of a large number oferyth- 
roid cells in suspension culture with sIL-6R, IL-6, and SCF 
has been provided by the proliferation, differentiation, and 
maturation  of  immature  erythroid  progenitors  in  the 
CD34 §  cell population.  To  confirm this,  we  carried  out 
methylcellulose clonal culture of purified CD34 + cells (Ta- 
ble 2). The combination of sIL-6R, IL-6, and SCF in the 
absence of EPO  stimulated  not  only erythroid bursts but 
many large erythroid mixed colonies as well,  all of which Figure 2.  Development oferythroid cells from CD34  + cells in culture with slL-6R, IL-6, and SCF. Cytocentrifuge  preparations of  suspension culture 
were stained with May-Griinwald-Giemsa at day 7 (a) and day 14 (d), or immunostained with antiglycophorin  A mAb (b) or antihemoglobin ot mAb (c) 
at day 14. In the 14-d methylcellulose culture with slL-6R, IL-6, and SCF, erythroid burst (e) and mixed erythroid colony (f) were generated from 
CD34  + cells. (a) ￿  (b-d) ￿  and (e and  f) ￿ 
also  contained  many  mature  erythroid  cells  including 
erythrocytes,  as shown in  Fig.  2,  e and f  In contrast,  nei- 
ther  erythroid  bursts  nor  erythroid  mixed  colonies  were 
observed  in  cultures  with  SCF  alone  or  in  combination 
with  IL-6.  Generation  of erythroid  bursts  and  erythroid 
mixed  colonies by the  combination  of slL-6R,  IL-6,  and 
SCF was also confirmed in serum-free cultures.  The num- 
ber of erythroid bursts with a combination of slL-6R, IL-6, 
and SCF is comparable with that induced by EPO alone or 
in combination with SCF or IL-3. A  combination of EPO 
with  SCF  or IL-3 also  supported  mixed  erythroid  colony 
formation,  but the  colony number was significantly lower 
than  that  supplemented  with  a  combination  of sIL-6R, 
IL-6, and SCF  (p  <0.005).  These  results  suggest that slL- 
6R,  IL-6,  and  SCF  may act on  the  same  progenitors  re- 
sponsive  to EPO,  as well as  earlier  progenitors  insensitive 
to EPO. 
When  we  cultured  BM  MNC  which  contain  CD34- 
mature  erythroid  progenitors  (i.e.,  CFU-E),  eflficient  for- 
mation  of erythroid  colonies  in  addition  to  a  number  of 
erythroid bursts and erythroid mixed colonies was also ob- 
served  in  the presence  of slL-6R,  IL-6, and  SCF in both 
serum-containing  and  serum-free  conditions  (Table  2). 
The number of erythroid colonies induced by this  combi- 
nation was comparable to that induced by a combination of 
EPO and SCF,  suggesting equal responsiveness  of CFU-E 
to EPO or to the slL-6R/IL-6 complex in the presence of 
SCF. It is interesting to note that slL-6R and IL-6 without 
SCF  also  induced  a  small  number  of erythroid  colonies 
from BM MNC  in both serum-containing and serum-free 
cultures,  implying that a part of CFU-E may respond to a 
complex ofslL-6R/IL-6 in the absence of SCF. 
These  results  in  clonal  studies  together  with  those  ob- 
tained in suspension culture clearly indicated that the com- 
bination of slL-6R,  IL-6, and SCF in the absence of EPO 
can support proliferation, differentiation,  and terminal mat- 
uration  (end-terminal  nuclear  condensation/enucleation) 
of not only immature erythroid progenitors in the CD34 § 
cell population but also of mature  erythroid progenitors in 
BM MNC. 
Effect of Anti-gp130  mAb,  Anti-IL-6R  mAb,  and  Anti- 
EPO Ab on the Generation of Erythroid Cell.  To test whether 
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 Table 2.  Generation  of Erythroid Colonies fiom  Cord Blood  CD34 + Cells and Adult BM MNC  in Methylcellulose  Culture 
Serum-containing  Serum-free 
Target cells  Stimuli  E  B  E-Mix  E  B  E-Mix 
CD34 + cells 
BM MNC 
SCF  0  0  0  0  0  0 
IL-6 +  SCF  0  0  0  0  0  0 
slL-6R +  IL-6  0  0  0  0  0  0 
slL-6R +  IL-6 +  SCF  0  28  +  65  102  -- 21  0  8  •  4  45  +  4 
EPO  0  35  +  15  0  0  6  +  2  0 
EPO  +  SCF  0  44 +  12  14 +  4*  0  14 +  3  4  +  la 
EPO  +  IL-3  0  41  +  9  8  +  7*  0  15  _+ 7  5  +  4* 
SCF  0  0  0  0  0  0 
IL-6 +  SCF  0  0  0  0  0  0 
slL-6P. +  IL-6  31  •  5  0  0  5  +  2  0  0 
slL-6P. +  IL-6 +  SCF  121  +  3  76 +  12  162  +  31  71  +  9  36 •  10  45  •  5 
EPO  102  •  15  73  -  21  0  70 +  14  40 •  8  0 
EPO  +  SCF  118  •  11  93  _+  19  16 +  4*  81  _  10  49  •  5  4  •  2* 
EPO  +IL3  98  •  99  •  15  8  •  76•  48  •  11  2  • 
500 CD34 + cells/m] or 2.5  ￿  104/ml ofBM MNC were initiated  in triplicate  culture and scored at day 7 for CFU-E-derived colonies,  and day 14 
for BFU-E and CFU-Mix-derived colonies.  Results represent mean +  SD from triplicate  cultures. 
Significantly different from slL-6R +  IL-6 +  SCF (*P <0.005, *P <0.0001), 
E, CFU-E-derived erythroid colonies;  B, BFU-E-derived erythroid bursts; E-Mix, CFU-Mix-derived erythroid mixed colonies. 
membrane-anchored  gpl30 was involved in slL-6R/IL-6-- 
mediated  erythropoiesis,  we  examined  the  effects  of anti- 
gp130 mAbs (GPX7, GPX22, and GPZ35), anti-IL-61K rnAb, 
and anti-EPO neutralizing Ab on the development oferyth- 
roid  cells  from  CD34 +  cells.  The  addition  of anti-gp130 
mAbs to the suspension culture with sIL-61k, IL-6, and SCF 
completely  abrogated  the  production  of  erythroid  cells, 
whereas these mAbs had no effect on EPO-dependent  pro- 
duction  of erythroid  cells (Fig.  3  A).  The addition of anti- 
IL-61K mAb at a  concentration  of 10  ~zg/ml to the culture 
resulted in almost complete inhibition  (Fig. 3  B). The rela- 
tively  lower  efficiency  of anti-IL-6R  mAb  compared  to 
that  of anti-gpl30  mAb may be explained by the presence 
of many  more  molecules  of sIL-6R  added  to  the  culture 
than those of cell surface gpl30 expressed on 2,000 CD34 + 
cells.  By contrast,  although  an  anti-EPO  Ab  almost  com- 
pletely  blocked  EPO-dependent  production  of erythroid 
cells, it failed to inhibit the generation of erythroid cells in- 
duced by the combination  of sIL-6tK,  IL-6,  and  SCF  (Fig. 
3  C).  Methylcellulose  clonal  culture  of CD34 +  cells  also 
indicated that anti-gpl30 mAbs but not anti-EPO Ab com- 
pletely  blocked  the  development  of both  erythroid  burst 
and  erythroid  mixed  colony  formation  stimulated  by  the 
combination ofsIL-6R, IL-6, and SCF. These results clearly 
demonstrate  that  the  observed  effects  of sIL-6R  and  IL-6 
were provided through  the interaction of the sIL-61K/IL-6 
complex to membrane-anchored  g-pl30 on the target cells. 
Our  results  also  indicated  that  the  generation  of erythroid 
cells  from  CD34 +  cells  by  gpl30  signaling  in  association 
with c-kit activation is independent  of EPO. 
120 
i  100 
80 
~  60 
0 
-~  20 
0-- 
0  0.1  1  10  0  0.1  1  10  0  0.;>4 2.4  24 
Anti-gp130 mAbs  Anti-lL.6R mAb  Anti-EPO Ab 
(l~g/ml) 
Figure 3.  Effects of various concentrations  of anti-human gp130 mAbs 
(A), anti-human IL-6P.  mAb (B), and anti-human EPO Ab (C) on the 
generation  of erythroid cells from CD34 + cells in suspension culture with 
a combination  ofslL-6R, IL-6, and SCF (open circles)  or a combination of 
EPO and SCF (filled circles).  The mAbs were added at the beginning of the 
culture  and results were determined at day 14. The wells without mAbs 
were estimated  as  control  experiments.  Total  erythroid  cells including 
erythroblast,  normoblast,  and  erythrocyte  were calculated based on the 
total cell number and the proportion of the erythroid cells determined  on 
the cytospin shdes. Data represent the ratio of the total erythroid  cells in 
each well treated  with mAbs to that  obtained  with control  and are ex- 
pressed as percent (%) control. 
842  Erythropoietin-independent Erythropoiesis by gpl30 and c-kit Signalings Discussion 
EPO has been shown as the principal factor that controls 
proliferation, differentiation, and apoptosis of human eryth- 
roid progenitor cells through its special cell surface receptor 
(EPOR)  signaling.  Several cytokines such  as  SCF,  IL-3, 
GM-CSF, IGF-1, and hepatocyte growth factor (HGF) were 
reported to enhance the proliferation and/or maturation of 
erythroid progenitors in vitro, but failed to do so without 
EPO, suggesting the central role of EPO in erythropoiesis 
(21-28). No factor so far has been reported to possess activ- 
ity similar to that of EPO, especially on relatively late stage 
erythroid progenitors.  In  the  present  paper,  we  demon- 
strate that combined signals through gp130 and c-kit could 
stimulate proliferation and maturation of immature as well 
as mature erythroid progenitors independent of EPO, giv- 
ing rise to a number of erythroblasts and erythrocytes. This 
indicates that EPOR signaling may not be obligatory for 
proliferation,  differentiation,  and  terminal  maturation  of 
normal human erythroid progenitor cells in vitro. 
Significant production of erythroid cells in culture with 
slL-6R in the presence of.IL-6 and SCF and lack of this 
production in  culture without sIL-6R  are reminiscent of 
the previously reported fact that sIL-6R confers IL-6 re- 
sponsiveness to cells that show no expression of IL-6R but 
do express gp130. This view was supported by our immuno- 
staining and flow cytometric analysis experiments in which 
all CD34 + cells from cord blood and proliferating cells in the 
sIL-6R/IL-6/SCF  culture expressed gp130, but in which 
most of the CD34 + cells appeared to be negative for IL-6R 
staining  (our unpublished data).  Thus, gp130 may be ex- 
pressed ubiquitously in erythroid progenitors. Activation of 
gp130, which can be initiated by a complex ofsIL-6R/IL-6 
but not IL-6 alone as shown in the present study, may trans- 
duce signals independent of EPOR to stimulate the devel- 
opment of erythroid cells.  Recent studies  (6,  7,  29)  have 
indicated that activation ofJAK2 kinase is associated with 
gp130 and EPOR signal transduction, implying that gp130 
and EPOR may share a common pathway for intracellular 
signaling in erythroid grogenitors. It is interesting to note 
that the observed synergy between gp130 and c-kit signal- 
ings on erythropoiesis is reminiscent of recent findings by 
Ip et al.  (30)  that CNTF signals  through gp130 synergize 
with FGF, which uses Kit-like receptor tyrosine kinase, for 
the  terminal  differentiation of neuronal  progenitor  cells. 
This suggests  that synergistic signals through the gp130 re- 
ceptor family and the receptors with  tyrosine kinase may 
have an important role in the development of  not only blood 
cells but neurons as well. 
The dramatic erythropoiesis supported by the coactiva- 
tion of both gpl30 and c-kit signal pathways in the absence 
of EPO might suggest that gp130 and c-kit signalings play a 
crucial role in the proliferation and maturation of erythroid 
cells  in vivo.  In fact,  previous studies  have  demonstrated 
that mice with  W or Steel (Sl) mutations developed severe 
anemia with  a repressed number of CFU-E  in fetal liver 
(28, 31-33); a recent gene-targeting experiment has shown 
that impaired  erythropoiesis was  observed in gp130-defi- 
cient  mice  (34).  Detailed  hemopoietic  analysis  of IL-6- 
deficient mice by Bernad et al. (35) also revealed that while 
having essential  hematological parameters and high BFU-E 
in BM and spleen in steady-state condition, the IL-6-defi- 
cient mice experienced severe anemia, a slow recovery rate, 
and higher mortality after induction of anemia, suggesting 
that erythroid differentiation is impaired by the absence of 
IL-6. Our present data also suggest that receptors presented 
in soluble form as well as expressed on cell surface play an 
important role in the development of hemopoiesis. It has 
been reported that the physiological significance of slL-6R 
is indicated by its detection in human sera (36, 37). slL-6R 
present in sera is biologically active in terms of its ability to 
bind IL-6 and eventually to stimulate gp130  (2, 8).  A  de- 
tectable effect ofslL-6R on the generation oferythroid cells 
from CD34 + cells in vitro was observed at concentrations 
of 80 ng/ml, which seems likely to be within the physio- 
logical range.  IL-6 and SCF are also  detectable in human 
sera.  In addition,  not only IL-6 but also both soluble and 
membrane-bound  forms  of SCF  are  produced  by  BM 
stroma  cells  that may anchor hemopoietic stem cells  and 
immature  progenitors  and  support  their  proliferation  in 
BM (37-40). Thus, the stimulators for initiating the activa- 
tion of  both gp130 and c-kit signal pathways seem sufficient 
in human physiological state.  Taken together, current re- 
sults suggest that gp130 signaling in combination with SCF 
play important roles on normal erythropoiesis in vivo. 
Our present data provide new insights into mechanisms 
that control proliferation, differentiation, and terminal mat- 
uration of human erythroid cells. More recently, Wu et al. 
(41) have demonstrated that whereas EPO or EPOR-defi- 
cient mice died of  failure oferythrocyte generation in murine 
definitive fetal liver erythropoiesis, low levels of EPO- and 
EPOR-independent  erythropoiesis do  occur in  primitive 
erythropoiesis at the yolk sac stage,  suggesting that another 
mechanism  may  play  a  critical  role.  Further  studies  are 
needed to elucidate (a) whether the novel mechanism with 
gp130, as demonstrated in this study, contributes to human 
erythropoiesis in vivo and (b) its possible different role and 
cooperation with EPO. 
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